Valeant — A Case Study In Rotten Culture And Business Ethics

Law360, New York (May 4, 2016, 11:06 AM EDT) -- The latest poster child for corporate malfeasance is Valeant Pharmaceuticals International Inc. The perfect enforcement storm is lining up with Congress, the U.S. Securities and Exchange Commission, and two U.S. attorney’s offices getting ready to aggressively investigate and punish Valeant and its principal leaders.

Congress is focusing on outrageous price increases in Valeant pharmaceuticals that have resulted in loud public complaints. The SEC and the U.S. attorney’s office in New York are reviewing Valeant for good old-fashioned fraud and accounting errors, and the U.S. attorney’s office...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.